Calico Company Drives Innovation in Healthcare and Aging

Calico is a life sciences company focused on aging and age-related diseases. It was founded in 2013 by Google's co-founders Larry Page and Sergey Brin.

Calico's mission is to understand the aging process and to develop new treatments for age-related diseases. The company is working on a range of projects to achieve this goal, including research into the biology of aging and the development of new therapies.

Calico has assembled a team of experts in aging and age-related diseases to lead its research efforts. The company is also collaborating with other organizations, including universities and pharmaceutical companies, to advance its research and development.

Suggestion: Related Companies

Calico is a life sciences company that focuses on aging biology and longevity research. They were founded by Google in 2013.

Calico's mission is to understand the biology of aging and to develop interventions that can increase human healthspan, which is the period of life spent in good health.

Their research focuses on understanding the underlying biology of aging and age-related diseases, such as cancer and neurodegenerative disorders.

Calico has been actively forming partnerships with leading research institutions and biopharmaceutical companies to accelerate its research on age-related diseases.

In 2014, Calico entered into a research partnership with AbbVie, a global biopharma company, to uncover and market novel treatments for age-related diseases such as neurodegeneration and cancer.

The partnership has been extended multiple times, with the latest expansion committing an additional $1 billion to the collaboration. This investment will see Calico responsible for research and early development until 2025 and advancing collaboration projects into Phase IIa through 2030.

AbbVie provides scientific and clinical development support, as well as commercial know-how to lead future development and commercialization efforts. Since joining forces, the companies have produced more than 20 early-stage programs for diseases across immuno-oncology and neurodegeneration.

Calico has also partnered with the Broad Institute of MIT and Harvard to advance the understanding of age-related diseases and translate findings into novel therapies. The collaboration leverages the institute's deep genetics and biology expertise to understand the mechanisms of ageing.

Consider reading: Banking Terms Pdf

In 2015, Calico teamed up with QB3 to conduct research into longevity and age-related diseases, with a focus on identifying and supporting QB3 research projects focused on the mechanisms of ageing. Calico has the option to obtain exclusive rights to discoveries made as a result of the sponsored research agreement.

One notable outcome of these partnerships is the development of ISRIB, an experimental drug that was found to reverse age-related declines in memory and mental flexibility in mice.

Calico Life Sciences is a research and development company focused on understanding the biology that controls human aging and lifespan. It was founded in 2013 and is based in South San Francisco, California.

Calico's work includes a drug-development pipeline, with collaborations with academia and industry to conduct research on age-related diseases. The company engages in the discovery and development of interventions aimed at addressing age-related diseases, utilizing advanced technologies and model systems.

Calico has filed 44 patents, with one recent patent being granted on December 3, 2024, for anti-papp-a antibodies and methods of use thereof. This patent is related to kidney diseases, rare diseases, monoclonal antibodies, the immune system, and immunology.

Calico is currently looking to fill various positions, including Senior Director, Head of Toxicology, and Director, Chemical Development. These roles are based in South San Francisco, California, and offer salaries ranging from $238,000 to $350,000 per year.

Some of the job openings at Calico include:

These job openings offer competitive salaries and are a great opportunity for individuals to be a part of Calico's mission to understand and address age-related diseases.

Calico's secrecy led to frustration among researchers, who questioned whether the company had produced any useful scientific advancements.

The company's press releases about research partnerships didn't provide enough information to satisfy curiosity.

Calico's purpose was to focus on long-term science not expected to yield results for 10 or more years, which left nothing to report on in its first five years.

For more insights, see: 5 Years

Calico's secrecy led to frustration among researchers regarding the company's lack of transparency about its research results and specifics of its work.

Google's formation of Calico kept many details under wraps, including whether the company would focus on biology or information technology.

The company issued press releases about research partnerships, but they were vague and didn't provide any concrete information about the results of its research.

Calico said its business purpose was to focus on long-term science that wouldn't yield results for 10 or more years, which left nothing to report on in its first five years.

Expand your knowledge: Focus Group Holdings Limited

Calico taps Mabwell’s anti-ageing antibody in $596m licensing deal. This significant investment is a major step forward in the fight against age-related diseases.

Alphabet's Calico has licensed the IL-11 drug from Mabwell, a Chinese biotech company. The deal is worth $596 million, a substantial amount that reflects the potential of this anti-ageing antibody.

The IL-11 drug has shown promise in targeting age-related diseases, and Calico plans to use it to tackle these conditions beyond China.

Worth a look: General Motors Chapter 11 Reorganization

Calico Life Sciences has a range of job openings across various departments. The company is headquartered in South San Francisco, CA.

Some of the job titles and corresponding salary ranges include: Senior Director, Head of Toxicology ($340,000 - $350,000), Director, Chemical Development ($238,000 - $250,000), and Principal Investigator, Cardiovascular Research ($220,000 - $241,000).

Here are some key job openings at Calico Life Sciences:

The company also has a team of experienced professionals, including the CEO at Calico Life Sciences.

Cynthia Kenyon is a renowned American geneticist who has made groundbreaking discoveries in the field of aging research. She is currently a Professor of Biochemistry and Biophysics at the University of California, San Francisco.

Kenyon's most notable work involves the discovery of the genetic mechanism that controls aging in nematode worms. Her research has led to a significant increase in our understanding of the aging process.

By studying the nematode worm, Kenyon's team was able to identify a gene called daf-2, which regulates aging and longevity. This discovery has far-reaching implications for the study of aging and age-related diseases.

Kenyon's work has also led to the development of new treatments for age-related diseases, such as Alzheimer's and Parkinson's. Her research has the potential to improve the quality of life for millions of people worldwide.

At Calico Life Sciences, you'll find a team of talented individuals working together to push the boundaries of human lifespan and healthspan. The company has a strong leadership presence, with a CEO at the helm.

The CEO at Calico Life Sciences oversees the entire organization, making strategic decisions to drive the company forward. Let's take a look at some of the key roles and their corresponding salary ranges.

Here are some of the key roles at Calico Life Sciences, along with their salary ranges:

These individuals play a crucial role in shaping the company's vision and direction. Whether you're a seasoned professional or just starting your career, Calico Life Sciences offers a range of opportunities to grow and develop your skills.